hcplive.com
Cure8 news brief
Subcutaneous Infliximab Outperforms IV in Ileal Crohn's Disease Analysis - HCPLive
Medications
Infliximab
Anti-TNF
Conference Abstract
Adult patients
Patients On Biologics
Clinicians
Researchers
Why This Matters
This analysis suggests a subcutaneous formulation of infliximab may lead to better clinical and endoscopic outcomes than intravenous infliximab for ileal-involved Crohn’s disease, which could affect treatment choices and patient convenience if confirmed.
Who Should Pay Attention
Adults with Crohn’s disease (especially ileal or ileocolonic disease), patients on or considering biologic therapy (infliximab), gastroenterologists, and IBD researchers.
Study Snapshot
Story typeResearch news
Evidence typeConference abstract
Source depthFull source text
What To Know
This report pooled patient-level data from four registrational trials (including the phase 3 LIBERTY-CD and PLANETCD trials) and then used 1:1 propensity score matching to compare standard maintenance regimens (SC infliximab 120 mg every 2 weeks vs IV infliximab 5 mg/kg every 8 weeks).
After matching (70 patients per group), SC infliximab was associated with higher rates of clinical remission, endoscopic response, and endoscopic remission at week 54. Drug exposure appeared relevant — higher steady-state serum infliximab concentrations correlated with endoscopic response in both groups.
What this does not show: The analysis pooled and matched trial data but is not a prospective randomized head-to-head trial; investigators called for prospective studies to confirm these findings. The presentation is a conference abstract/analysis, not a full peer-reviewed randomized comparison.
Keep In Mind
Findings come from a pooled, propensity score–matched analysis presented at a scientific meeting; it is not the same as a randomized head-to-head trial and requires prospective confirmation. The analysis also noted baseline differences between groups before matching and a relatively small matched sample size.
Source Details
Review the original publication for the complete reporting, methods, and context.
Conference abstract
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationhcplive.com
PublisherHCPLive
AuthorsAbigail Brooks, MA
Indexed viaGoogle News
Source typeWeb article
PublishedOct 14, 2026, 2:52 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Effectiveness of anti-TNF therapy after prior ustekinumab exposure in Crohn’s disease: A propensity-weighted cohort study
Patients and clinicians often need evidence about whether switching from ustekinumab to an anti‑TNF (infliximab or adalimumab) still gives meaningful clinical responses. This study suggests many patients can respond, but...
Pharmacokinetic Predictor of Infection in Patients With Inflammatory Bowel Disease Treated With Intravenous and Subcutaneous Infliximab.
This study suggests that cumulative infliximab exposure over time (AUC) — not just trough levels — may predict infection risk in people with IBD. That could affect how clinicians use therapeutic drug monitoring to...
Patterns and factors associated with dose escalation during maintenance treatment for inflammatory bowel disease: a population-based cohort study.
Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...